At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 62 enrolled
Drug / intervention
CT-P17 SC AI (adalimumab)biological
Likely dose
CT-P17 SC AI (adalimumab) 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Moderate to Severe Active Rheumatoid Arthritis
In Brief
A Phase 3 clinical trial evaluating CT-P17 SC AI (adalimumab) for Rheumatoid Arthritis. Completed, enrolled 62 participants across 1 site.
Detailed Summary
Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
CountriesPoland
CollaboratorsPPD Development, LP
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartSep 2019
Primary CompletionNov 2019
First PostedNov 2019
Study CompletionApr 2020
TodayJul 2026
First PostedNov 20, 2019
Enrollment StartSep 9, 2019
Primary CompletionNov 4, 2019
Study CompletionApr 24, 2020
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 6.6 years ago
Interventions
CT-P17 SC AI (adalimumab)biological
Subcutaneous Injection of Adalimumab 40mg once every two weeks